(Photo: Roche)
Switzerland-based biotechnology giant Roche plans to invest $50 billion in the United States in the next five years. These investments will further strengthen Roche’s U.S. footprint with 13 manufacturing and 15 research and development (R&D) sites across the Pharmaceutical and Diagnostics Divisions. The projects are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.
As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight U.S. states. The investment will include:
Expanded and upgraded U.S. manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California
A state-of-the-art gene therapy manufacturing facility in Pennsylvania
A new 900,000-square-foot manufacturing center to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
A new manufacturing facility for continuous glucose monitoring in Indiana
A new R&D center in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for new cardiovascular, renal and metabolism R&D efforts
Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California
Dr. Thomas Schinecker, Roche Group CEO (Photo: Roche)
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the U.S.,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the U.S., across both our Pharmaceutical and Diagnostics Divisions. Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world.”
Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the U.S. than it imports. Currently, its diagnostics division has an export surplus from the U.S. to other countries.